Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
78.38
-0.52 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
December 19, 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
Via
MarketBeat
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
December 13, 2022
From
AstraZeneca
Via
Business Wire
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
December 08, 2022
From
AstraZeneca
Via
Business Wire
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
December 08, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
December 07, 2022
From
AstraZeneca
Via
Business Wire
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
November 30, 2022
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
December 01, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
November 30, 2022
From
AstraZeneca
Via
Business Wire
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
November 28, 2022
From
C4X Discovery Holdings plc
Via
GlobeNewswire
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
November 22, 2022
From
AstraZeneca
Via
Business Wire
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
November 16, 2022
From
Alexion, AstraZeneca Rare Disease
Via
Business Wire
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
November 11, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
November 10, 2022
From
AstraZeneca
Via
Business Wire
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 09, 2022
From
AstraZeneca
Via
Business Wire
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
October 27, 2022
From
Alexion
Via
Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
October 24, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
October 20, 2022
From
AstraZeneca
Via
Business Wire
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
October 18, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
Exposures
COVID-19
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
October 12, 2022
From
Alexion
Via
Business Wire
Is Illumina Still the Gamechanger in Genomics Sequencing?
October 04, 2022
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Via
MarketBeat
Topics
Earnings
Economy
Lawsuit
Exposures
Financial
Legal
Supply Chain
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
October 03, 2022
From
Alexion
Via
Business Wire
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
September 16, 2022
From
Alexion
Via
Business Wire
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
September 15, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
September 12, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
September 11, 2022
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.